China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
WALTHAM, Mass., March 01, 2016 -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended December 31, 2015 on March 10, 2016 before the market opens.
Histogenics’ management will host a conference call on Thursday, March 10, 2016 at 8:30 a.m. EST. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “60614260” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics’ website for approximately 60 days following the presentation.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
